Argument: Patent licenses are very costly, impair R and D
- Debate: Gene patents, con argument.
Michael Crichton. "Patenting Life." New York Times (Op-Ed). February 13, 2007: "Apologists for gene patents argue that the issue is a tempest in a teapot, that patent licenses are readily available at minimal cost. That’s simply untrue. The owner of the genome for Hepatitis C is paid millions by researchers to study this disease. Not surprisingly, many other researchers choose to study something less expensive."